Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This study found that treating dogs with benign prostatic hyperplasia using osaterone acetate reduced prostatic volume and increased diffusion times of an ultrasound contrast agent, suggesting effective treatment and potential for CEUS monitoring.

This case report discusses a young woman who developed bilateral osteonecrosis of the femoral head after corticosteroid treatment for alopecia areata, underscoring the risk of this complication in patients undergoing such therapy.

This correspondence describes the dermoscopic features of an osteonevus of Nanta but does not report new clinical findings.

This article updates on the medical management of benign prostatic hyperplasia in companion animals and reports no new clinical findings; the authors discuss existing treatments.

This source reviews existing studies on treating canine noninflammatory alopecia, identifying microneedling and oral administration of certain drugs as optimal methods with fewer side effects, while noting that other treatments like mitotane and minoxidil cause serious side effects, limiting their future use.

This case study reports that bisphosphonate therapy, used to treat osteoporosis, can lead to jawbone necrosis, as demonstrated in an 82-year-old patient who experienced severe complications requiring surgical intervention. The authors recommend comprehensive dental care before and avoidance of invasive procedures during bisphosphonate treatment.

This review outlines the oral toxic effects of chemotherapy and stresses the need for evaluating dental health prior to treatment to mitigate these complications, but it reports no new clinical results.

This review discusses the therapeutic properties of polydeoxyribonucleotides derived from marine organisms for wound healing and inflammation, but it reports no new clinical results.

This review compiles evidence from 20 relevant studies and suggests that platelet-rich plasma-derived extracellular vesicles represent a promising therapeutic option in regenerative medicine, although the authors emphasize the need for standardized protocols due to inconsistencies across studies.

This abstract lists keywords related to various medications and therapies, but it does not provide new study results or findings.

Finasteride effectively lowers specific hormone levels, helping monitor treatment progress.

Higher IGF-1 levels in hair follicles link to better finasteride results for hair loss.

This study suggests that finasteride's effect on promoting hair growth in men with androgenetic alopecia may be due to its inhibition of 5aR2 localized in hair follicles.

This study observed that androgenic alopecia patients taking finasteride had altered neuroactive steroid levels and persistent depression symptoms even after stopping the treatment.

This study found that 1-year use of 5alpha-reductase inhibitors, dutasteride or finasteride, significantly lowered dihydrotestosterone levels without adversely affecting bone density, lipids, or hemoglobin in normal men.

This study explored the interaction between androgen and Wnt signaling in dermal papilla cells, targeting the effects of androgen on hair growth reduction.

This study suggests that Botox injections may increase hair count and reduce hair loss in men with androgenetic alopecia, potentially through increased blood flow and oxygen to the scalp.

This study found that both finasteride and flutamide effectively reduced hirsutism, with flutamide being more effective than finasteride in decreasing hirsutism scores and hair diameter over 12 months.

This review discusses the potential role of androgen receptor CAG repeat polymorphism testing in hypogonadism management for both sexes, but its clinical utility remains unclear and requires further investigation.

This study developed a theoretical model that suggests finasteride may completely inhibit 5AR type 2, but not sufficiently suppress type 1, leading to only partial reduction of dihydrotestosterone at clinical doses.

This study found that topical fluridil increased the anagen hair percentage in men with androgenetic alopecia without causing irritation or systemic absorption over 9 months.

Finasteride treats hair loss but may affect prostate cancer detection.

This study found that topical fluridil increased the anagen percentage in men with androgenetic alopecia without causing irritation or systemic side effects.

This study found that some synthesized 17-oximino-5-androsten-3β-yl esters demonstrated stronger cytotoxicity and antiandrogenic activity against prostate cancer cells than finasteride.

This study found that IL-17A-producing γδ T cells play a key role in bone fracture healing by promoting bone formation, with deficiencies leading to impaired repair in mice.

This study found that androgenetic alopecia in asymptomatic young men was associated with increased arterial stiffness, as measured by the cardio-ankle vascular index.